The U.S. Food and Drug Administration (FDA) has outlined a new regulatory framework that could accelerate access to individualized therapies for patients with ultra-rare diseases, Pharmaphorum reports. The approach is based on the concept of a “plausible mechanism,” first introduced in November last year.<\/p>\n\n
If finalized, the guidance will enable patients with diseases that have a clearly established biological mechanism\u2014but with case numbers too small for standard clinical trials\u2014to gain faster access to treatment.<\/p>\n\n
The new framework envisages that innovative technologies such as genome editing and RNA-based therapies could be approved based on “one adequate and well-controlled clinical investigation with confirmatory evidence.”<\/p>\n\n
According to the FDA, the sample size in this context will inevitably be small, but results must be sufficiently compelling to rule out chance findings. Standard approval will require evidence of actual improvement in clinical outcomes. The well-documented natural history of the disease in untreated patients may be used as an additional basis for comparison. <\/p>\n\n
To fall within the scope of the new regulatory pathway, the disease must have a clearly defined mechanism\u2014a genetic, cellular, or molecular defect\u2014at which the therapy is directed. Developers must demonstrate that the treatment acts directly on the root cause or on a closely linked biological pathway. <\/p>\n\n
Health and Human Services Secretary Robert F. Kennedy Jr. stated that the new framework aims to reduce unnecessary bureaucracy and synchronize regulation with modern biology so that breakthrough therapies reach patients in need more quickly. <\/p>\n\n
FDA Commissioner Marty Makary noted that approximately 30 million people in the U.S. live with a rare disease\u2014about one in every 11 Americans. However, fewer than 5% of the more than 10,000 known rare diseases have an approved treatment, according to the National Organization for Rare Disorders (NORD). <\/p>\n\n
One reason is the lack of economic return for pharmaceutical companies when developing therapies for ultra-rare conditions. The new framework is expected to make it easier for academic centers and clinical teams to advance such therapies. <\/p>\n\n
The FDA also recalled the case of “Baby KJ”\u2014the first patient treated with a personalized in vivo CRISPR gene therapy designed to correct a specific mutation.<\/p>\n\n
The draft guidance is subject to a 60-day public comment period, after which the regulator will consider its final adoption.<\/p>\n","protected":false},"excerpt":{"rendered":"
The U.S. Food and Drug Administration (FDA) has outlined a new regulatory framework that could accelerate access to individualized therapies for patients with ultra-rare diseases, Pharmaphorum reports. The approach is based on the concept of a “plausible mechanism,” first introduced in November last year. If finalized, the guidance will enable patients with diseases that have […]<\/p>\n","protected":false},"author":2,"featured_media":5568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jet_sm_ready_style":"","_jet_sm_style":"","_jet_sm_controls_values":"","_jet_sm_fonts_collection":"","_jet_sm_fonts_links":"","footnotes":""},"categories":[96],"tags":[],"class_list":["post-5567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\n